Detailed analysis of the mechanism of action and immune regulation of abatacept (Enresu)

Abatacept is a recombinant fusion protein composed of extracellular cytotoxic Tlymphocyte antigen-4 (CTLA-4) fragment is fused to the immunoglobulinG1 (IgG1) constant region. Its main mechanism of action is to regulate the activity of the immune system by selectively inhibiting TT cell co-stimulatory signals. In a normal immune response, the activation of T cells not only requires antigen presentation, but also depends on costimulatory signals (the combination of CD80/CD86 and CD28). Abatacept blocks this costimulatory signal by binding to CD80/CD86 on the surface of antigen-presenting cells, thereby inhibiting the excessive activation of T cells.

In autoimmune diseases, such as rheumatoid arthritis (RA), abnormal activation of T cells can lead to the massive release of inflammatory factors and damage to self-tissue. Abatacept indirectly reduces the production of pro-inflammatory cytokines, such as TNF-α, IL-1, and IL-6, by inhibiting T cell activation, thereby reducing joint inflammation, bone destruction, and synovial hyperplasia. This mechanism allows abatacept to achieve precise immune regulation without completely suppressing the entire immune system, reducing the risk of infection caused by systemic immune suppression.

Abatacept not only regulates the inflammatory response of arthritis, but also affects B cell function and autoantibody production. TActivation inhibition will reduce the stimulation of helper B cells, thereby reducing the production of autoantibodies (such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies), further mitigating the progression of autoimmune diseases. In addition, abatacept's immunomodulatory effect is selective and mainly targets abnormally activated T cells, while having relatively little impact on normal immune surveillance functions, which is one of the reasons for its high clinical safety.

Clinically, abatacept is usually administered via intravenous or subcutaneous injection and is used in patients with moderately to severely active rheumatoid arthritis, especially for patients with traditional DMARDs(disease-modifying antirheumatic drugs) in patients who have had an inadequate response to treatment. Its immunomodulatory effects maintain inflammation control and joint protection over the long term. At the same time, patients using abatacept still need to regularly monitor infection risks, immune function, and liver and kidney indicators to ensure medication safety. In future research, the immunomodulatory mechanism of abatacept will also provide new ideas and potential application directions for the treatment of other autoimmune diseases.

Reference link:https://www.drugs.com